Aardvark Pauses 2 Obesity Trials, Reveals New Details on Cardiac Concerns

Why It Matters

The suspension underscores safety challenges for gut‑hormone obesity drugs and could delay market entry while dampening investor confidence.

Key Takeaways

• Cardiac anomalies detected at double therapeutic dose of ARD‑101.
• POWER and STRENGTH Phase 2 obesity trials placed on hold.
• HERO Phase 3 trial for Prader‑Willi syndrome also suspended.
• Shares fell >69% YTD, trading around $4 per share.
• FDA review will determine future path for ARD‑101/ARD‑201.

Pulse Analysis

The obesity market has been reshaped by GLP‑1 agonists, yet many companies are seeking next‑generation agents that amplify gut‑derived satiety signals. Aardvark Therapeutics entered this space with ARD‑101, a molecule that activates intestinal taste receptors to boost endogenous GLP‑1, and its derivative ARD‑201, which pairs the receptor agonist with a DPP‑4 inhibitor to extend hormone exposure. By targeting the upstream pathway rather than delivering GLP‑1 directly, the platform promised weight‑loss efficacy with potentially lower dosing frequency, positioning the firm as a potential challenger to established players such as Novo Nordisk and Eli Lilly.

The recent cardiac observations have abruptly shifted that narrative. In a routine safety study, two healthy volunteers receiving 1,600 mg of ARD‑101 twice daily—double the intended therapeutic exposure—exhibited echocardiographic changes suggestive of reduced cardiac efficiency. Although the company described the findings as reversible, the decision to halt enrollment in the Phase 3 HERO trial and pause the Phase 2 POWER and STRENGTH studies reflects heightened regulatory scrutiny of cardiovascular risk in obesity therapeutics. Similar concerns have surfaced with other gut‑hormone combos, prompting the FDA to demand robust cardiac endpoints before granting approval.

Investor sentiment turned sharply negative, with Aardvark’s stock sliding more than 69 % year‑to‑date to around $4 per share. The pause not only delays potential revenue from a multi‑billion‑dollar obesity market but also raises questions about the viability of the company’s broader pipeline, including the Prader‑Willi syndrome program. Moving forward, Aardvark must work closely with the FDA to redesign dosing regimens, conduct thorough cardiac monitoring, and possibly explore lower‑dose strategies. The outcome will signal how quickly the industry can reconcile innovative mechanisms with stringent safety expectations.